Lupin informs about company updates

27 May 2019 Evaluate

Lupin has informed that the Company has received a communication from the US FDA classifying the inspection conducted at its Goa facility between January 28 to February 8, 2019 as Official Action Indicated (OAI). The US FDA has stated that this facility may be subject to regulatory or administrative action and that it may withhold approval of any pending applications or supplements in which this facility is listed. The inspection at the Goa facility had closed with two observations. Based on US FDA's Concept of Operations program, the Company understands that the status of the facility is still under review. The Company does not believe that this inspection classification will have an impact on disruption of supplies or the existing revenues from operations of this facility. The Company is in the process of sending further updates of its corrective actions to the US FDA and is hopeful of a positive outcome. This is considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.

Lupin Share Price

2195.00 18.20 (0.84%)
14-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1700.55
Dr. Reddys Lab 1186.45
Cipla 1434.60
Zydus Lifesciences 884.00
Lupin 2195.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×